Wolfgang Miesbach on Linus Völker’s Presentation of Caplacizumab as Frontline Therapy for iTTP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Caplacizumab as Frontline Therapy for iTTP: Is Plasmapheresis Still Needed? Priv.-Doz. Dr.med. Linus Völker presented at ASH compelling evidence that caplacizumab can work without plasma exchange in selected patients.
Systematic evidence: >100 plasma-free iTTP episodes
· First case reports and small series: ~10 episodes
· Kühne et al., Blood 2024 (Austria/Germany): 42 episodes with 90.5% clinical response without TPE and a median time to platelet normalization: 3 days (vs. 4 days with TPE, p=0.31), however, 4 patients required rescue TPE
· Knöbl, ISTH 2025: 34 episodes
· MAYARI Trial, ISTH 2025: 46 episodes and 93.5% remission without TPE (43/46 patients), 95.7% remission overall (44/46 patients)
This strategy is off-label and requires institutional capabilities:
✓ Extensive iTTP treatment experience at specialized centers
✓ 24/7 ADAMTS13 activity measurement (turnaround in hours, not days)
✓ Immediate caplacizumab access via emergency pharmacy
✓ Plasma exchange instantly available (safety net, not routine)
✓ No contraindications to caplacizumab therapy
Crucial to identify the right patient
There are clinical characteristics favoring a plasma-free approach
· Immediate platelet recovery after the first caplacizumab dose
· Clinically stable condition at presentation
· Lower LDH levels at onset
· Less severe organ involvement (lower ICU admission rates)
A fascinating glimpse into how frontline caplacizumab, in the right setting with the right patient, may allow truly plasma-free management for selected iTTP cases.”
All from ASH25 featured in Hemostasis Today.
-
Mar 16, 2026, 13:32Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk
-
Mar 16, 2026, 13:12Mariia Kumskova։ New Insights Into Platelet Dysfunction in Ehlers-Danlos Syndrome
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data